Company intelligence / Profile preview

Vibliome Therapeutics

Bozeman, Montana, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Vibliome has developed a systematic approach for small molecule Type-II kinase inhibitors with unique profiles and high selectivity. The company has executed an Asset Sale and License Agreement with Beartooth Therapeutics for two proprietary kinase inhibitor programs for oncology indications[2].

Therapeutic areas: OncologyPulmonologyImmunologyMen's Health
Modalities: Small molecule kinase inhibitors
Industry: Biotech

Partnerships

Deerfield ManagementBeartooth Therapeutics

Beyond the preview

Go deeper on Vibliome Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibliome Therapeutics.

Explore the full profile